USTMA New Guidance

The USTMA physicians have collaborated and created a document giving guidance on the diagnosis, treatment, and outpatient follow up of patients with TTP.


Drs. Mazepa and Cataland formed the United States Thrombotic Microangiopathy (USTMA) Consortium in 2014 as a grassroots effort to organize research efforts in the thrombotic microangiopathies. Both physicians have received research funding from the Foundation.

The term thrombotic microangiopathy or TMA represents a broad pathophysiologic process that leads to the development of a microangiopathic hemolytic anemia (MAHA) (characterized by fragmented cells or schistocytes in the peripheral blood) and thrombocytopenia. TTP is one of those disorders.

The USTMA now incorporates 15 large US referral centers with:

  1. a large referral base of patients with TMAs (which includes patients with TTP)
  2. a minimum of 1 site leader with a career interest in clinical/translational research in TMA 
  3. adequate clinical/translational research facilities and resources to participate in these research activities

This is not an Answering TTP Foundation publication, and any questions should be directed to the contact information on the event website. NB: Mention of any treatment products associated with this event are provided for information only and their inclusion is not an endorsement of a particular product or company by Answering TTP Foundation.